Fig. 01 -

Title Slide

Fig. 02 -

Disclosures

Fig. 03 -

Definition

Fig. 04 -

Scope

Fig. 05 -

Normal, Moderate, Severe

Fig. 06 -

Vertebral Compression Fractures

Fig. 07 -

Hip Fractures

Fig. 08 -

Bone Health Physiology

Fig. 09 -

Bone Physiology

Fig. 10 -

Screening and Guidelines

Fig. 11 -

Osteoporotic Fracture Risk

Fig. 12 -

FRAX

Fig. 13 -

Evaluation

Fig. 14 -

Thyroid and Bone

Fig. 15 -

Thyroid Effects

Fig. 16 -

Hyperthyroidism

Fig. 17 -

Markers

Fig. 18 -

Markers (Cont.)

Fig. 19 -

Prevention

Fig. 20 -

Treatment

Fig. 21 -

Calcium and Vitamin D

Fig. 22 -

Anti-Resorptive & Anabolic

Fig. 23 -

Postmenopausal Treatment

Fig. 24 -

Bisphosphonates

Fig. 25 -

Continuous Increases

Fig. 26 -

Zoledronic Acid

Fig. 27 -

Zoledronic Acid (Cont.)

Fig. 28 -

Denosumab

Fig. 29 -

FREEDOM Trial

Fig. 30 -

Anabolic Therapy

Fig. 31 -

Teriparatide versus Oral Bisphos

Fig. 32 -

Anti-Sclerostin Antibody

Fig. 33 -

DXA Data

Fig. 34 -

Romosozumab

Fig. 35 -

Exercise and Osteoporosis

Fig. 36 -

Monitoring and follow up

Fig. 37 -

Case 1

Fig. 38 -

DXA Results

Fig. 39 -

Secondary Causes

Fig. 40 -

Secondary Evaluation

Fig. 41 -

Case 1 Management

Fig. 42 -

Case 2

Fig. 43 -

Osteoporosis in Men

Fig. 44 -

Case 2 (cont.)

Fig. 45 -

Bisphosphonate Holiday

Fig. 46 -

Case 3

Fig. 47 -

Teriparatide

Fig. 48 -

Risk Reduction

Fig. 49 -

64 Yr Old Woman

Fig. 50 -

Summary

Fig. 51 -

Question 1

Fig. 52 -

Question 2

Fig. 53 -

Question 3